Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| tyrosine kinase inhibitors | 5280 | 901119-35-5 |
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
None
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -1.340 | High | 0.92 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 68.234 | High | 0.92 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.372 | 10^-6 cm/s | High | 0.92 |
| dh-clint | Dog hepatocyte intrinsic clearance | 13.183 | uL/min/10^6 cells | High | 0.92 |
| dppb | Dog plasma protein binding (% unbound) | 1.280 | % | High | 0.92 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 1.300 | % | High | 0.92 |
| herg | hERG pIC50 | 4.535 | pIC50 | High | 0.92 |
| hh-clint | Human hepatocyte intrinsic clearance | 32.434 | uL/min/10^6 cells | High | 0.92 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.673 | uL/min/mg protein | High | 0.92 |
| hppb | Human plasma protein binding (% unbound) | 0.480 | % | High | 0.92 |
| kinase-safety-class | AAK1,ABL1,ABL2,ACVR1B,ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BLK,BMX,BRAF,BTK,CAMK1,CAMK2A,CAMK2B,CAMK2D,CAMK2G,CDK1,CDK14,CDK16,CDK19,CDK2,CDK3,CDK4,CDK5,CDK6,CDK7,CDK9,CHEK1,CHEK2,CHUK,CLK1,CLK2,CLK4,CSF1R,CSK,CSNK1G1,CSNK1G2,CSNK2A2,DDR1,DYRK1A,DYRK1B,DYRK2,DYRK3,EGFR,EIF2AK3,EPHA2,EPHB1,EPHB4,ERBB2,ERBB4,FGFR1,FGFR4,FLT1,FLT3,FLT4,FYN,GAK,GRK1,GRK2,GSK3A,GSK3B,HASPIN,HIPK2,IGF1R,IKBKB,INSR,INSRR,IRAK1,IRAK3,IRAK4,ITK,JAK1,JAK2,JAK3,KDR,KIT,LCK,LRRK2,LYN,MAP2K1,MAP2K4,MAP2K6,MAP2K7,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K19,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP3K9,MAP4K1,MAP4K2,MAP4K3,MAP4K5,MAPK1,MAPK10,MAPK12,MAPK3,MAPK7,MAPK8,MAPK9,MARK1,MARK2,MARK3,MARK4,MELK,MET,MINK1,MKNK2,MST1R,MTOR,NTRK1,NTRK2,NTRK3,NUAK1,PAK1,PAK2,PAK4,PAK5,PDGFRB,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PIM3,PLK1,PLK2,PLK3,PLK4,PRKAA1,PRKAA2,PRKACA,PRKCD,PRKCI,PRKCZ,PRKD1,PRKDC,PTK2,PTK6,RET,RIPK1,RIPK3,ROCK2,RPS6KA1,SGK1,SIK2,SIK3,SRC,STK10,STK16,STK17A,STK3,STK33,STK4,SYK,TBK1,TEK,TGFBR1,TNIK,TNK1,TTK,TYRO3,UHMK1,ULK1,ULK2,YES1,ZAP70 | 182 | |||
| kinase-selectivity-class | AAK1,ABL2,ACVR2A,ACVR2B,ALK,AURKA,AURKB,AURKC,AXL,BLK,BMX,BRAF,CAMK2A,CAMK2B,CAMK2D,CDK1,CDK16,CDK2,CDK3,CDK4,CDK6,CDK7,CDK9,CHEK1,CLK2,CLK4,CSF1R,DDR1,DYRK1B,DYRK2,EGFR,EPHA2,EPHB4,ERBB2,ERBB4,FGFR1,FLT1,FLT3,FLT4,FYN,GAK,GRK2,GSK3A,GSK3B,IGF1R,IKBKB,INSR,IRAK1,IRAK3,IRAK4,JAK1,JAK2,JAK3,KDR,KIT,LCK,LRRK2,LYN,MAP2K1,MAP2K3,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K21,MAP3K7,MAP3K9,MAP4K1,MAP4K3,MAP4K5,MAPK1,MAPK12,MAPK7,MAPK8,MARK1,MARK2,MARK4,MET,MINK1,MKNK2,MST1R,NTRK1,NTRK3,NUAK1,PAK1,PAK4,PAK5,PDGFRB,PDK1,PDK4,PIK3CA,PIK3CD,PIK3CG,PRKAA1,PRKAA2,PRKCD,PRKDC,PTK2,RET,RIPK3,SIK2,SIK3,SRC,STK10,STK16,STK33,SYK,TEK,TNIK,TTK,TYRO3,ULK1,ULK2,YES1,ZAP70 | 116 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 4.121 | High | 0.92 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 118.304 | High | 0.92 | |
| mppb | Mouse plasma protein binding (% unbound) | 1.440 | High | 0.92 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.484 | High | 0.92 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 1.590 | % | High | 0.92 |
| rh-clint | Rat hepatocyte intrinsic clearance | 102.329 | uL/min/10^6 cells | High | 0.92 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 56.920 | % | High | 0.92 |
| rppb | Rat plasma protein binding (% unbound) | 0.470 | % | High | 0.92 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 924.698 | uM | High | 0.92 |
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 9, 2020 | EMA | Instituto Grifols S.A. | |
| April 17, 2018 | FDA | RIGEL PHARMS INC | |
| Dec. 23, 2022 | PMDA | Kissei Pharmaceutical Co., Ltd. |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Platelet count | 164.16 | 43.94 | 18 | 1254 | 34 | 90627141 |
| Platelet count decreased | 163.80 | 43.94 | 64 | 1208 | 136905 | 90490270 |
| Diarrhoea | 84.88 | 43.94 | 83 | 1189 | 939107 | 89688068 |
| Hepatic function abnormal | 70.83 | 43.94 | 26 | 1246 | 46262 | 90580913 |
| Product prescribing issue | 68.61 | 43.94 | 17 | 1255 | 7962 | 90619213 |
| Hospitalisation | 65.21 | 43.94 | 33 | 1239 | 128067 | 90499108 |
| Death | 55.76 | 43.94 | 48 | 1224 | 456503 | 90170672 |
| Platelet count increased | 44.43 | 43.94 | 15 | 1257 | 20844 | 90606331 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Platelet count | 112.91 | 49.81 | 13 | 795 | 30 | 42620497 |
| Platelet count decreased | 110.47 | 49.81 | 53 | 755 | 138528 | 42481999 |
| Death | 55.26 | 49.81 | 55 | 753 | 471130 | 42149397 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Platelet count decreased | 130.76 | 37.29 | 63 | 1432 | 230380 | 110357424 |
| Platelet count | 107.37 | 37.29 | 13 | 1482 | 79 | 110587725 |
| Hepatic function abnormal | 94.74 | 37.29 | 38 | 1457 | 89257 | 110498547 |
| Diarrhoea | 82.57 | 37.29 | 88 | 1407 | 1139417 | 109448387 |
| Death | 66.96 | 37.29 | 63 | 1432 | 698806 | 109888998 |
| Hypertension | 60.65 | 37.29 | 52 | 1443 | 510032 | 110077772 |
| Platelet count increased | 57.04 | 37.29 | 19 | 1476 | 26315 | 110561489 |
| Platelet count abnormal | 47.54 | 37.29 | 12 | 1483 | 6270 | 110581534 |
| Splenectomy | 44.21 | 37.29 | 8 | 1487 | 862 | 110586942 |
| Product prescribing issue | 39.12 | 37.29 | 12 | 1483 | 12760 | 110575044 |
None
| Source | Code | Description |
|---|---|---|
| ATC | B02BX09 | BLOOD AND BLOOD FORMING ORGANS ANTIHEMORRHAGICS VITAMIN K AND OTHER HEMOSTATICS Other systemic hemostatics |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:33281 | antimicrobial agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35842 | antirheumatic drug |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| CHEBI has role | CHEBI:233423 | antifibrotic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Immune thrombocytopenia | indication | 2897005 | DOID:1587 |
| Chronic idiopathic thrombocytopenic purpura | indication | 13172003 |
None
None
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 1.54 | acidic |
| pKa2 | 6.59 | acidic |
| pKa3 | 5.0 | Basic |
| pKa4 | 4.34 | Basic |
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 100MG BASE | TAVALISSE | RIGEL PHARMS | N209299 | April 17, 2018 | RX | TABLET | ORAL | 9266912 | Jan. 19, 2026 | TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT |
| EQ 150MG BASE | TAVALISSE | RIGEL PHARMS | N209299 | April 17, 2018 | RX | TABLET | ORAL | 9266912 | Jan. 19, 2026 | TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT |
| EQ 100MG BASE | TAVALISSE | RIGEL PHARMS | N209299 | April 17, 2018 | RX | TABLET | ORAL | 7538108 | March 28, 2026 | TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT |
| EQ 150MG BASE | TAVALISSE | RIGEL PHARMS | N209299 | April 17, 2018 | RX | TABLET | ORAL | 7538108 | March 28, 2026 | TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT |
| EQ 100MG BASE | TAVALISSE | RIGEL PHARMS | N209299 | April 17, 2018 | RX | TABLET | ORAL | 7989448 | June 12, 2026 | TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT |
| EQ 150MG BASE | TAVALISSE | RIGEL PHARMS | N209299 | April 17, 2018 | RX | TABLET | ORAL | 7989448 | June 12, 2026 | TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT |
| EQ 100MG BASE | TAVALISSE | RIGEL PHARMS | N209299 | April 17, 2018 | RX | TABLET | ORAL | 8163902 | June 17, 2026 | TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT |
| EQ 100MG BASE | TAVALISSE | RIGEL PHARMS | N209299 | April 17, 2018 | RX | TABLET | ORAL | 8912170 | June 17, 2026 | TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT |
| EQ 100MG BASE | TAVALISSE | RIGEL PHARMS | N209299 | April 17, 2018 | RX | TABLET | ORAL | 9283238 | June 17, 2026 | TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT |
| EQ 150MG BASE | TAVALISSE | RIGEL PHARMS | N209299 | April 17, 2018 | RX | TABLET | ORAL | 8163902 | June 17, 2026 | TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT |
| EQ 150MG BASE | TAVALISSE | RIGEL PHARMS | N209299 | April 17, 2018 | RX | TABLET | ORAL | 8912170 | June 17, 2026 | TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT |
| EQ 150MG BASE | TAVALISSE | RIGEL PHARMS | N209299 | April 17, 2018 | RX | TABLET | ORAL | 9283238 | June 17, 2026 | TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT |
| EQ 100MG BASE | TAVALISSE | RIGEL PHARMS | N209299 | April 17, 2018 | RX | TABLET | ORAL | 8951504 | July 27, 2032 | TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT |
| EQ 150MG BASE | TAVALISSE | RIGEL PHARMS | N209299 | April 17, 2018 | RX | TABLET | ORAL | 8951504 | July 27, 2032 | TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT |
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Tyrosine-protein kinase SYK | Kinase | INHIBITOR | IC50 | 7.39 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| Macrophage-stimulating protein receptor | Kinase | Kd | 6.33 | CHEMBL | |||||
| ATP-binding cassette sub-family G member 2 | Transporter | IC50 | 7.30 | CHEMBL | |||||
| Platelet-derived growth factor receptor beta | Kinase | Kd | 8.48 | CHEMBL | |||||
| Tyrosine-protein kinase ABL1 | Kinase | Kd | 6.77 | CHEMBL | |||||
| Mast/stem cell growth factor receptor Kit | Kinase | Kd | 8.60 | CHEMBL | |||||
| Epidermal growth factor receptor | Kinase | Kd | 7.21 | CHEMBL | |||||
| Proto-oncogene tyrosine-protein kinase Src | Kinase | Kd | 8.08 | CHEMBL | |||||
| Tyrosine-protein kinase Lck | Kinase | Kd | 7.52 | CHEMBL | |||||
| Tyrosine-protein kinase Yes | Kinase | Kd | 7.46 | CHEMBL | |||||
| Tyrosine-protein kinase Fyn | Kinase | Kd | 7.55 | CHEMBL | |||||
| Ephrin type-A receptor 2 | Kinase | Kd | 6.85 | CHEMBL | |||||
| RAF proto-oncogene serine/threonine-protein kinase | Kinase | Kd | 6.08 | CHEMBL | |||||
| Serine/threonine-protein kinase B-raf | Kinase | Kd | 6.62 | CHEMBL | |||||
| Receptor-type tyrosine-protein kinase FLT3 | Kinase | Kd | 9.43 | CHEMBL | |||||
| Proto-oncogene tyrosine-protein kinase receptor Ret | Kinase | INHIBITOR | IC50 | 8.30 | IUPHAR | ||||
| Vascular endothelial growth factor receptor 1 | Kinase | Kd | 7.80 | CHEMBL | |||||
| Vascular endothelial growth factor receptor 2 | Kinase | Kd | 7.16 | CHEMBL | |||||
| Vascular endothelial growth factor receptor 3 | Kinase | Kd | 8.04 | CHEMBL | |||||
| Macrophage colony-stimulating factor 1 receptor | Kinase | Kd | 7.51 | CHEMBL | |||||
| Platelet-derived growth factor receptor alpha | Kinase | Kd | 7.22 | CHEMBL | |||||
| Ribosomal protein S6 kinase alpha-3 | Kinase | Kd | 5.10 | CHEMBL | |||||
| Phosphorylase b kinase gamma catalytic chain, liver/testis isoform | Kinase | Kd | 6.03 | CHEMBL | |||||
| Insulin-like growth factor 1 receptor | Kinase | Kd | 5.89 | CHEMBL | |||||
| Myosin light chain kinase, smooth muscle | Kinase | Kd | 5.19 | CHEMBL | |||||
| Insulin receptor | Kinase | Kd | 5.96 | CHEMBL | |||||
| Death-associated protein kinase 3 | Kinase | Kd | 7.89 | CHEMBL | |||||
| Calcium/calmodulin-dependent protein kinase type 1 | Kinase | Kd | 6.64 | CHEMBL | |||||
| Mitogen-activated protein kinase 8 | Kinase | EC50 | 8 | CHEMBL | |||||
| Fibroblast growth factor receptor 3 | Kinase | Kd | 7.25 | CHEMBL | |||||
| Rho-associated protein kinase 1 | Kinase | Kd | 6.23 | CHEMBL | |||||
| Focal adhesion kinase 1 | Kinase | Kd | 6.60 | CHEMBL | |||||
| Tyrosine-protein kinase HCK | Kinase | Kd | 6.82 | CHEMBL | |||||
| Tyrosine-protein kinase JAK1 | Kinase | Kd | 7.68 | CHEMBL | |||||
| Serine/threonine-protein kinase PLK1 | Kinase | Kd | 6.08 | CHEMBL | |||||
| Receptor tyrosine-protein kinase erbB-4 | Kinase | Kd | 6.22 | CHEMBL | |||||
| Mitogen-activated protein kinase 10 | Kinase | Kd | 7.43 | CHEMBL | |||||
| Death-associated protein kinase 2 | Kinase | Kd | 7.21 | CHEMBL | |||||
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Kinase | Kd | 5.38 | CHEMBL | |||||
| High affinity nerve growth factor receptor | Kinase | Kd | 6.77 | CHEMBL | |||||
| Protein kinase C delta type | Kinase | Kd | 5.39 | CHEMBL | |||||
| cAMP-dependent protein kinase catalytic subunit beta | Kinase | Kd | 6.29 | CHEMBL | |||||
| Tyrosine-protein kinase JAK2 | Kinase | Kd | 8.46 | CHEMBL | |||||
| Rho-associated protein kinase 2 | Kinase | Kd | 6.25 | CHEMBL | |||||
| Calcium/calmodulin-dependent protein kinase type II subunit delta | Kinase | Kd | 5.52 | CHEMBL | |||||
| Tyrosine-protein kinase CSK | Kinase | Kd | 6.80 | CHEMBL | |||||
| Angiopoietin-1 receptor | Kinase | Kd | 6.51 | CHEMBL | |||||
| Ephrin type-A receptor 8 | Kinase | Kd | 5.89 | CHEMBL | |||||
| Calcium/calmodulin-dependent protein kinase type II subunit gamma | Kinase | Kd | 6.04 | CHEMBL | |||||
| AP2-associated protein kinase 1 | Kinase | Kd | 6.39 | CHEMBL | |||||
| Serine/threonine-protein kinase MARK2 | Kinase | Kd | 6.55 | CHEMBL | |||||
| Hepatocyte growth factor receptor | Kinase | Kd | 6.64 | CHEMBL | |||||
| Tyrosine-protein kinase Lyn | Kinase | Kd | 7.58 | CHEMBL | |||||
| Cytoplasmic tyrosine-protein kinase BMX | Kinase | Kd | 6.75 | CHEMBL | |||||
| Serine/threonine-protein kinase Nek2 | Kinase | Kd | 6.58 | CHEMBL | |||||
| LIM domain kinase 1 | Kinase | Kd | 6.21 | CHEMBL | |||||
| 5'-AMP-activated protein kinase catalytic subunit alpha-1 | Kinase | Kd | 6.52 | CHEMBL | |||||
| Fibroblast growth factor receptor 1 | Kinase | Kd | 7.36 | CHEMBL | |||||
| Calcium/calmodulin-dependent protein kinase type II subunit alpha | Kinase | Kd | 5.96 | CHEMBL | |||||
| Serine/threonine-protein kinase 17B | Kinase | Kd | 8.04 | CHEMBL | |||||
| Serine/threonine-protein kinase 10 | Kinase | Kd | 7.16 | CHEMBL | |||||
| Tyrosine-protein kinase Fer | Kinase | Kd | 6.89 | CHEMBL | |||||
| Serine/threonine-protein kinase PLK4 | Kinase | Kd | 8.38 | CHEMBL | |||||
| Aurora kinase C | Kinase | Kd | 7.39 | CHEMBL | |||||
| Serine/threonine-protein kinase 16 | Kinase | Kd | 8.77 | CHEMBL | |||||
| Dual specificity protein kinase TTK | Kinase | Kd | 5.96 | CHEMBL | |||||
| Abelson tyrosine-protein kinase 2 | Kinase | Kd | 6.14 | CHEMBL | |||||
| Ephrin type-A receptor 5 | Kinase | Kd | 6.07 | CHEMBL | |||||
| Ephrin type-A receptor 4 | Kinase | Kd | 6.82 | CHEMBL | |||||
| Fibroblast growth factor receptor 2 | Kinase | Kd | 7.14 | CHEMBL | |||||
| Serine/threonine-protein kinase N1 | Kinase | Kd | 6.18 | CHEMBL | |||||
| Serine/threonine-protein kinase 17A | Kinase | Kd | 7.50 | CHEMBL | |||||
| Ephrin type-A receptor 6 | Kinase | Kd | 6.92 | CHEMBL | |||||
| TRAF2 and NCK-interacting protein kinase | Kinase | Kd | 5.89 | CHEMBL | |||||
| Mitogen-activated protein kinase 12 | Kinase | Kd | 6.41 | CHEMBL | |||||
| Tyrosine-protein kinase Fgr | Kinase | Kd | 7.48 | CHEMBL | |||||
| Aurora kinase A | Kinase | Kd | 7.53 | CHEMBL | |||||
| ALK tyrosine kinase receptor | Kinase | Kd | 6.62 | CHEMBL | |||||
| Serine/threonine-protein kinase 36 | Kinase | Kd | 6.64 | CHEMBL | |||||
| Ephrin type-A receptor 3 | Kinase | Kd | 6.44 | CHEMBL | |||||
| BMP-2-inducible protein kinase | Kinase | Kd | 5.72 | CHEMBL | |||||
| Tyrosine-protein kinase FRK | Kinase | Kd | 7.17 | CHEMBL | |||||
| Dual specificity protein kinase CLK1 | Kinase | Kd | 5.92 | CHEMBL | |||||
| Dual specificity protein kinase CLK2 | Kinase | Kd | 5.80 | CHEMBL | |||||
| Dual specificity protein kinase CLK3 | Kinase | Kd | 5.72 | CHEMBL | |||||
| Mitogen-activated protein kinase kinase kinase 4 | Kinase | Kd | 6.08 | CHEMBL | |||||
| Cyclin-G-associated kinase | Kinase | Kd | 6.60 | CHEMBL | |||||
| Glycogen synthase kinase-3 beta | Kinase | Kd | 6.92 | CHEMBL | |||||
| Receptor-interacting serine/threonine-protein kinase 2 | Kinase | Kd | 6.01 | CHEMBL | |||||
| Ephrin type-B receptor 1 | Kinase | Kd | 6.41 | CHEMBL | |||||
| Calcium/calmodulin-dependent protein kinase type 1D | Kinase | Kd | 6.70 | CHEMBL | |||||
| Activated CDC42 kinase 1 | Kinase | Kd | 7.16 | CHEMBL | |||||
| Ephrin type-A receptor 7 | Kinase | Kd | 7.41 | CHEMBL | |||||
| Ribosomal protein S6 kinase alpha-5 | Kinase | Kd | 6.82 | CHEMBL | |||||
| STE20-like serine/threonine-protein kinase | Kinase | Kd | 7.48 | CHEMBL | |||||
| Dual specificity protein kinase CLK4 | Kinase | Kd | 6.69 | CHEMBL | |||||
| MAP kinase-interacting serine/threonine-protein kinase 2 | Kinase | Kd | 6.89 | CHEMBL | |||||
| Mitogen-activated protein kinase 9 | Kinase | EC50 | 8 | CHEMBL | |||||
| MAP/microtubule affinity-regulating kinase 3 | Kinase | Kd | 5.72 | CHEMBL | |||||
| Calcium/calmodulin-dependent protein kinase type 1G | Kinase | Kd | 6.34 | CHEMBL | |||||
| Epithelial discoidin domain-containing receptor 1 | Kinase | Kd | 8.03 | CHEMBL | |||||
| Ephrin type-B receptor 4 | Kinase | Kd | 6.22 | CHEMBL | |||||
| Testis-specific serine/threonine-protein kinase 1 | Kinase | Kd | 6 | CHEMBL | |||||
| Activin receptor type-1B | Kinase | Kd | 5.96 | CHEMBL | |||||
| Activin receptor type-1 | Kinase | Kd | 5.32 | CHEMBL | |||||
| Inhibitor of nuclear factor kappa-B kinase subunit beta | Kinase | Kd | 7.15 | CHEMBL | |||||
| 3-phosphoinositide-dependent protein kinase 1 | Kinase | Kd | 6.92 | CHEMBL | |||||
| TGF-beta receptor type-2 | Kinase | Kd | 6.48 | CHEMBL | |||||
| Dual specificity mitogen-activated protein kinase kinase 1 | Kinase | Kd | 6.50 | CHEMBL | |||||
| Dual specificity mitogen-activated protein kinase kinase 2 | Kinase | Kd | 6.14 | CHEMBL | |||||
| Tyrosine-protein kinase ITK/TSK | Kinase | Kd | 6.40 | CHEMBL | |||||
| Tyrosine-protein kinase ZAP-70 | Kinase | Kd | 7.68 | CHEMBL | |||||
| Glycogen synthase kinase-3 alpha | Kinase | Kd | 5.60 | CHEMBL | |||||
| Protein-tyrosine kinase 6 | Kinase | Kd | 6.44 | CHEMBL | |||||
| Tyrosine-protein kinase BTK | Kinase | Kd | 6.72 | CHEMBL | |||||
| Tyrosine-protein kinase Tec | Kinase | Kd | 5.80 | CHEMBL | |||||
| Tyrosine-protein kinase receptor UFO | Kinase | Kd | 7.09 | CHEMBL | |||||
| BDNF/NT-3 growth factors receptor | Kinase | Kd | 6.05 | CHEMBL | |||||
| Tyrosine-protein kinase receptor TYRO3 | Kinase | Kd | 5.72 | CHEMBL | |||||
| Ephrin type-B receptor 2 | Kinase | Kd | 6.06 | CHEMBL | |||||
| Cyclin-dependent kinase 7 | Kinase | Kd | 5.11 | CHEMBL | |||||
| Serine/threonine-protein kinase N2 | Kinase | Kd | 5.58 | CHEMBL | |||||
| Serine/threonine-protein kinase DCLK3 | Kinase | Kd | 6.22 | CHEMBL | |||||
| Serine/threonine-protein kinase 3 | Kinase | Kd | 5.52 | CHEMBL | |||||
| NUAK family SNF1-like kinase 2 | Kinase | Kd | 7.19 | CHEMBL | |||||
| Non-receptor tyrosine-protein kinase TNK1 | Kinase | Kd | 7.60 | CHEMBL | |||||
| Non-receptor tyrosine-protein kinase TYK2 | Kinase | Kd | 6.72 | CHEMBL | |||||
| Mitogen-activated protein kinase 13 | Kinase | Kd | 6.16 | CHEMBL | |||||
| Serine/threonine-protein kinase Chk1 | Kinase | Kd | 5.60 | CHEMBL | |||||
| Serine/threonine-protein kinase PAK 3 | Kinase | Kd | 6.16 | CHEMBL | |||||
| Cyclin-dependent kinase 17 | Kinase | Kd | 6.48 | CHEMBL | |||||
| Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha | Kinase | Kd | 5.72 | CHEMBL | |||||
| Phosphatidylinositol 5-phosphate 4-kinase type-2 beta | Kinase | Kd | 5.92 | CHEMBL | |||||
| Myosin light chain kinase family member 4 | Kinase | Kd | 6.09 | CHEMBL | |||||
| Wee1-like protein kinase | Kinase | Kd | 6.05 | CHEMBL | |||||
| Serine/threonine-protein kinase 25 | Kinase | Kd | 5.04 | CHEMBL | |||||
| Protein-tyrosine kinase 2-beta | Kinase | Kd | 7.54 | CHEMBL | |||||
| Serine/threonine-protein kinase RIO1 | Kinase | Kd | 6.47 | CHEMBL | |||||
| Tyrosine-protein kinase receptor Tie-1 | Kinase | Kd | 7.12 | CHEMBL | |||||
| Serine/threonine-protein kinase tousled-like 1 | Kinase | Kd | 6.31 | CHEMBL | |||||
| Serine/threonine-protein kinase tousled-like 2 | Kinase | Kd | 6.42 | CHEMBL | |||||
| NT-3 growth factor receptor | Kinase | Kd | 6.24 | CHEMBL | |||||
| Tyrosine-protein kinase TXK | Kinase | Kd | 6.85 | CHEMBL | |||||
| Casein kinase II subunit alpha | Kinase | Kd | 7.19 | CHEMBL | |||||
| Casein kinase II subunit alpha' | Kinase | Kd | 7.85 | CHEMBL | |||||
| Inhibitor of nuclear factor kappa-B kinase subunit epsilon | Kinase | Kd | 7.89 | CHEMBL | |||||
| LIM domain kinase 2 | Kinase | Kd | 5.85 | CHEMBL | |||||
| Serine/threonine-protein kinase STK11 | Kinase | Kd | 5.47 | CHEMBL | |||||
| Dual specificity mitogen-activated protein kinase kinase 3 | Kinase | Kd | 7 | CHEMBL | |||||
| MAP kinase-interacting serine/threonine-protein kinase 1 | Kinase | Kd | 6.64 | CHEMBL | |||||
| Serine/threonine-protein kinase Nek7 | Kinase | Kd | 7.96 | CHEMBL | |||||
| Eukaryotic translation initiation factor 2-alpha kinase 4 | Kinase | Kd | 8.48 | CHEMBL | |||||
| Insulin receptor-related protein | Kinase | Kd | 5.34 | CHEMBL | |||||
| Interleukin-1 receptor-associated kinase 3 | Kinase | Kd | 7.96 | CHEMBL | |||||
| Serine/threonine-protein kinase RIO3 | Kinase | Kd | 6.68 | CHEMBL | |||||
| Serine/threonine-protein kinase SIK2 | Kinase | Kd | 7.11 | CHEMBL | |||||
| SRSF protein kinase 1 | Kinase | Kd | 6.23 | CHEMBL | |||||
| Serine/threonine-protein kinase 33 | Kinase | Kd | 6.01 | CHEMBL | |||||
| Serine/threonine-protein kinase TNNI3K | Kinase | Kd | 6.51 | CHEMBL | |||||
| 5'-AMP-activated protein kinase catalytic subunit alpha-2 | Kinase | Kd | 6.12 | CHEMBL | |||||
| Ankyrin repeat and protein kinase domain-containing protein 1 | Kinase | Kd | 6.48 | CHEMBL | |||||
| Discoidin domain-containing receptor 2 | Kinase | Kd | 7.37 | CHEMBL | |||||
| Chaperone activity of bc1 complex-like, mitochondrial | Kinase | Kd | 5.96 | CHEMBL | |||||
| Serine/threonine-protein kinase LATS1 | Kinase | Kd | 5.67 | CHEMBL | |||||
| Serine/threonine-protein kinase LATS2 | Kinase | Kd | 5.40 | CHEMBL | |||||
| Leukocyte tyrosine kinase receptor | Kinase | Kd | 6.10 | CHEMBL | |||||
| Mitogen-activated protein kinase kinase kinase kinase 1 | Kinase | Kd | 5.85 | CHEMBL | |||||
| Serine/threonine-protein kinase PAK 6 | Kinase | Kd | 6.51 | CHEMBL | |||||
| Serine/threonine-protein kinase PAK 7 | Kinase | Kd | 7.16 | CHEMBL | |||||
| NUAK family SNF1-like kinase 1 | Kinase | Kd | 7.12 | CHEMBL | |||||
| cAMP-dependent protein kinase catalytic subunit alpha | Kinase | Kd | 6.22 | CHEMBL | |||||
| Mitogen-activated protein kinase kinase kinase kinase 3 | Kinase | Kd | 5.62 | CHEMBL | |||||
| Aurora kinase B | Kinase | Kd | 6.96 | CHEMBL | |||||
| Tyrosine-protein kinase Blk | Kinase | Kd | 7.60 | CHEMBL | |||||
| Serine/threonine-protein kinase MARK1 | Kinase | Kd | 6.57 | CHEMBL | |||||
| MAP/microtubule affinity-regulating kinase 4 | Kinase | Kd | 7.05 | CHEMBL | |||||
| Dual specificity mitogen-activated protein kinase kinase 4 | Kinase | Kd | 6.70 | CHEMBL | |||||
| Dual specificity mitogen-activated protein kinase kinase 6 | Kinase | Kd | 6.32 | CHEMBL | |||||
| Tyrosine-protein kinase Mer | Kinase | Kd | 6.77 | CHEMBL | |||||
| Mitogen-activated protein kinase kinase kinase 9 | Kinase | Kd | 8.37 | CHEMBL | |||||
| Mitogen-activated protein kinase kinase kinase 10 | Kinase | Kd | 8.42 | CHEMBL | |||||
| Mitogen-activated protein kinase kinase kinase 11 | Kinase | Kd | 7.96 | CHEMBL | |||||
| Muscle, skeletal receptor tyrosine-protein kinase | Kinase | Kd | 7 | CHEMBL | |||||
| Citron Rho-interacting kinase | Kinase | Kd | 6.36 | CHEMBL | |||||
| Death-associated protein kinase 1 | Kinase | Kd | 7.26 | CHEMBL | |||||
| Serine/threonine-protein kinase Nek5 | Kinase | Kd | 7.89 | CHEMBL | |||||
| Serine/threonine-protein kinase Nek9 | Kinase | Kd | 7.80 | CHEMBL | |||||
| Serine/threonine-protein kinase PAK 1 | Kinase | Kd | 6.58 | CHEMBL | |||||
| Serine/threonine-protein kinase PAK 2 | Kinase | Kd | 6.47 | CHEMBL | |||||
| Serine/threonine-protein kinase PAK 4 | Kinase | Kd | 7.02 | CHEMBL | |||||
| AarF domain-containing protein kinase 4 | Kinase | Kd | 7.19 | CHEMBL | |||||
| Serine/threonine-protein kinase SIK1 | Kinase | Kd | 7.28 | CHEMBL | |||||
| Tyrosine-protein kinase Srms | Kinase | Kd | 6.21 | CHEMBL | |||||
| Dual specificity testis-specific protein kinase 1 | Kinase | Kd | 6.44 | CHEMBL | |||||
| TGF-beta receptor type-1 | Kinase | Kd | 5.58 | CHEMBL | |||||
| Ephrin type-A receptor 1 | Kinase | Kd | 7.17 | CHEMBL | |||||
| Serine/threonine-protein kinase PLK3 | Kinase | Kd | 8.29 | CHEMBL | |||||
| Mitogen-activated protein kinase 15 | Kinase | Kd | 6.19 | CHEMBL | |||||
| Serine/threonine-protein kinase D3 | Kinase | Kd | 5.41 | CHEMBL | |||||
| cGMP-dependent protein kinase 2 | Kinase | Kd | 5.44 | CHEMBL | |||||
| Interferon-induced, double-stranded RNA-activated protein kinase | Kinase | Kd | 6.75 | CHEMBL | |||||
| Tyrosine-protein kinase Fes/Fps | Kinase | Kd | 6.70 | CHEMBL | |||||
| Fibroblast growth factor receptor 4 | Kinase | Kd | 6.46 | CHEMBL | |||||
| Proto-oncogene tyrosine-protein kinase ROS | Kinase | Kd | 7.54 | CHEMBL | |||||
| Ribosomal protein S6 kinase alpha-1 | Kinase | Kd | 6.31 | CHEMBL | |||||
| Ribosomal protein S6 kinase alpha-4 | Kinase | Kd | 7.36 | CHEMBL | |||||
| Mitogen-activated protein kinase kinase kinase kinase 2 | Kinase | Kd | 6.17 | CHEMBL | |||||
| Serine/threonine-protein kinase TBK1 | Kinase | Kd | 7.64 | CHEMBL | |||||
| Interleukin-1 receptor-associated kinase 4 | Kinase | Kd | 6.85 | CHEMBL | |||||
| Cyclin-dependent kinase-like 2 | Kinase | Kd | 5.23 | CHEMBL | |||||
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Kinase | Kd | 6.58 | CHEMBL | |||||
| Dual specificity tyrosine-phosphorylation-regulated kinase 2 | Kinase | Kd | 6.33 | CHEMBL | |||||
| Ephrin type-B receptor 6 | Kinase | Kd | 6.51 | CHEMBL | |||||
| Serine/threonine-protein kinase/endoribonuclease IRE1 | Kinase | Kd | 5.80 | CHEMBL | |||||
| Rhodopsin kinase | Kinase | Kd | 6.06 | CHEMBL | |||||
| G protein-coupled receptor kinase 4 | Kinase | Kd | 6.35 | CHEMBL | |||||
| G protein-coupled receptor kinase 7 | Kinase | Kd | 5.70 | CHEMBL | |||||
| Homeodomain-interacting protein kinase 2 | Kinase | Kd | 5.32 | CHEMBL | |||||
| Homeodomain-interacting protein kinase 3 | Kinase | Kd | 5.50 | CHEMBL | |||||
| Homeodomain-interacting protein kinase 4 | Kinase | Kd | 5.55 | CHEMBL | |||||
| Inhibitor of nuclear factor kappa-B kinase subunit alpha | Kinase | Kd | 6.92 | CHEMBL | |||||
| Interleukin-1 receptor-associated kinase 1 | Kinase | Kd | 8.01 | CHEMBL | |||||
| Mitogen-activated protein kinase kinase kinase 2 | Kinase | Kd | 7.03 | CHEMBL | |||||
| Mitogen-activated protein kinase kinase kinase 3 | Kinase | Kd | 6.82 | CHEMBL | |||||
| Serine/threonine-protein kinase 38 | Kinase | Kd | 5.03 | CHEMBL | |||||
| Serine/threonine-protein kinase NIM1 | Kinase | Kd | 6.18 | CHEMBL | |||||
| Serine/threonine-protein kinase OSR1 | Kinase | Kd | 5.51 | CHEMBL | |||||
| Serine/threonine-protein kinase RIO2 | Kinase | Kd | 5.47 | CHEMBL | |||||
| SRSF protein kinase 3 | Kinase | Kd | 6.40 | CHEMBL | |||||
| Mitogen-activated protein kinase kinase kinase 7 | Kinase | Kd | 7.31 | CHEMBL | |||||
| Serine/threonine-protein kinase TAO1 | Kinase | Kd | 6.31 | CHEMBL | |||||
| Tyrosine-protein kinase JAK3 | Kinase | Kd | 7.44 | CHEMBL | |||||
| Serine/threonine-protein kinase ULK1 | Kinase | Kd | 7.85 | CHEMBL | |||||
| Serine/threonine-protein kinase ULK2 | Kinase | Kd | 7.72 | CHEMBL | |||||
| Serine/threonine-protein kinase ULK3 | Kinase | Kd | 8.15 | CHEMBL | |||||
| Mitogen-activated protein kinase kinase kinase 19 | Kinase | Kd | 7.17 | CHEMBL | |||||
| Homeodomain-interacting protein kinase 1 | Kinase | Kd | 6.09 | CHEMBL | |||||
| Serine/threonine-protein kinase PLK2 | Kinase | Kd | 7.47 | CHEMBL | |||||
| Receptor-interacting serine/threonine-protein kinase 4 | Kinase | Kd | 6.66 | CHEMBL | |||||
| Uncharacterized serine/threonine-protein kinase SBK3 | Kinase | Kd | 6.72 | CHEMBL | |||||
| Serine/threonine-protein kinase 35 | Kinase | Kd | 5.85 | CHEMBL | |||||
| Phosphatidylinositol 4-kinase beta | Kinase | Kd | 6.03 | CHEMBL | |||||
| Wee1-like protein kinase 2 | Kinase | Kd | 5.03 | CHEMBL | |||||
| Bone morphogenetic protein receptor type-1B | Kinase | Kd | 6.14 | CHEMBL | |||||
| Serine/threonine-protein kinase SBK1 | Kinase | Kd | 7.03 | CHEMBL | |||||
| Serine/threonine-protein kinase 32A | Kinase | Kd | 5.64 | CHEMBL | |||||
| Serine/threonine-protein kinase Nek3 | Kinase | Kd | 6.77 | CHEMBL | |||||
| Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma | Kinase | Kd | 6.89 | CHEMBL | |||||
| Serine/threonine-protein kinase TAO2 | Kinase | Kd | 6.19 | CHEMBL | |||||
| Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma | Kinase | Kd | 6.92 | CHEMBL | |||||
| Dual specificity mitogen-activated protein kinase kinase 5 | Kinase | Kd | 7.39 | CHEMBL | |||||
| Serine/threonine-protein kinase Nek11 | Kinase | Kd | 6.77 | CHEMBL | |||||
| Leucine-rich repeat serine/threonine-protein kinase 2 | Kinase | Kd | 7.57 | CHEMBL | |||||
| Serine/threonine-protein kinase Nek6 | Kinase | Kd | 8.20 | CHEMBL | |||||
| Ferrochelatase, mitochondrial | Enzyme | Kd | 5.51 | CHEMBL | |||||
| Serine/threonine-protein kinase Nek4 | Kinase | Kd | 5.75 | CHEMBL | |||||
| Bromodomain testis-specific protein | Nuclear other | IC50 | 4.68 | CHEMBL | |||||
| Serine/threonine-protein kinase Nek1 | Kinase | Kd | 6.77 | CHEMBL | |||||
| Myosin-10 | Enzyme | Kd | 6.64 | CHEMBL | |||||
| Cyclin-dependent kinase-like 1 | Kinase | Kd | 5.68 | CHEMBL | |||||
| Uncharacterized aarF domain-containing protein kinase 1 | Kinase | Kd | 7.62 | CHEMBL | |||||
| Adenosine receptor A3 | GPCR | INHIBITOR | IC50 | 7.09 | SCIENTIFIC LITERATURE | ||||
| Serine/threonine-protein kinase TAO3 | Kinase | Kd | 5.34 | CHEMBL | |||||
| Serine/threonine-protein kinase PknB | Kinase | Kd | 7.47 | CHEMBL | |||||
| Mast/stem cell growth factor receptor Kit | Kinase | EC50 | 7.34 | CHEMBL |
| ID | Source |
|---|---|
| SQ8A3S5101 | UNII |
| 914295-16-2 | SECONDARY_CAS_RN |
| 4037543 | VANDF |
| C2713632 | UMLSCUI |
| CHEBI:750486 | CHEBI |
| 2RC | PDB_CHEM_ID |
| CHEMBL2103830 | ChEMBL_ID |
| 11671467 | PUBCHEM_CID |
| DB12010 | DRUGBANK_ID |
| CHEMBL3989516 | ChEMBL_ID |
| D09347 | KEGG_DRUG |
| 9022 | INN_ID |
| C523665 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7796 | IUPHAR_LIGAND_ID |
| DB07159 | DRUGBANK_ID |
| 772033003 | SNOMEDCT_US |
| 772039004 | SNOMEDCT_US |
| C4730994 | UMLSCUI |
| CHEMBL475251 | ChEMBL_ID |
| 841290-80-0 | SECONDARY_CAS_RN |
| 276522 | MMSL |
| d08782 | MMSL |
| 11213558 | PUBCHEM_CID |
| 017516 | NDDF |
| 017517 | NDDF |
| 5706 | IUPHAR_LIGAND_ID |
| 2044896 | RXNORM |
| RC3A285J2G | UNII |
| CHEBI:91348 | CHEBI |
| RC3A285J2G | INXIGHT DRUGS |
| SQ8A3S5101 | INXIGHT DRUGS |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| TAVALISSE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71332-001 | TABLET | 100 mg | ORAL | NDA | 28 sections |
| TAVALISSE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71332-001 | TABLET | 100 mg | ORAL | NDA | 28 sections |
| TAVALISSE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71332-002 | TABLET | 150 mg | ORAL | NDA | 28 sections |
| TAVALISSE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71332-002 | TABLET | 150 mg | ORAL | NDA | 28 sections |